Loading...
WhiteOak Capital Pharma and Healthcare Fund Direct Growth
EquitySector - HealthcareVery High Risk
Direct
NAV (21-Nov-24)
₹12.970.45%1D
Returns (Since Inception)
29.74%
Rated ★4.5+ on 
Fund Overview
Fund Size
₹232 Cr
Expense Ratio
0.68%
ISIN
INF03VN01886
Minimum SIP
₹500
Exit Load
1.00%
Inception Date
06 Feb 2024
About this fund
This fund has been in existence for 9 months and 16 days, having been launched on 06-Feb-24.
As of 21-Nov-24, it has a Net Asset Value (NAV) of ₹12.97, Assets Under Management (AUM) of 231.99 Crores, and an expense ratio of 0.68%.
As of 21-Nov-24, it has a Net Asset Value (NAV) of ₹12.97, Assets Under Management (AUM) of 231.99 Crores, and an expense ratio of 0.68%.
- WhiteOak Capital Pharma and Healthcare Fund Direct Growth has given a CAGR return of 29.74% since inception.
- The fund's asset allocation comprises around 85.20% in equities, 0.00% in debts, and 14.80% in cash & cash equivalents.
- You can start investing in WhiteOak Capital Pharma and Healthcare Fund Direct Growth with a SIP of ₹500 or a Lumpsum investment of ₹500.
Performance against Category Average
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
Since Inception
+29.74%
— (Cat Avg.)
Portfolio Summaryas of 31st October 2024
| Equity | ₹197.66 Cr | 85.20% |
| Others | ₹34.33 Cr | 14.80% |
Top Holdings
All Holdings
Equity
Debt & Others
| Name | Type  | Amount | Holdings |
|---|---|---|---|
| Clearing Corporation Of India Ltd | Cash - Repurchase Agreement | ₹22.28 Cr | 9.60% |
| Sun Pharmaceuticals Industries Ltd | Equity | ₹22.22 Cr | 9.58% |
| Cipla Ltd | Equity | ₹12.83 Cr | 5.53% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹11.85 Cr | 5.11% |
| Poly Medicure Ltd | Equity | ₹8.34 Cr | 3.59% |
| Aurobindo Pharma Ltd | Equity | ₹8.1 Cr | 3.49% |
| Mankind Pharma Ltd | Equity | ₹7.61 Cr | 3.28% |
| Lupin Ltd | Equity | ₹7.47 Cr | 3.22% |
| Divi's Laboratories Ltd | Equity | ₹6.2 Cr | 2.67% |
| Krishna Institute of Medical Sciences Ltd | Equity | ₹6.1 Cr | 2.63% |
| Piramal Pharma Ltd | Equity | ₹6.02 Cr | 2.60% |
| Ipca Laboratories Ltd | Equity | ₹5.95 Cr | 2.56% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹5.91 Cr | 2.55% |
| Dr Reddy's Laboratories Ltd | Equity | ₹5.63 Cr | 2.43% |
| Strides Pharma Science Ltd | Equity | ₹4.99 Cr | 2.15% |
| Ajanta Pharma Ltd | Equity | ₹4.82 Cr | 2.08% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹4.8 Cr | 2.07% |
| Neuland Laboratories Limited | Equity | ₹4.76 Cr | 2.05% |
| Vijaya Diagnostic Centre Ltd | Equity | ₹4.52 Cr | 1.95% |
| Fortis Healthcare Ltd | Equity | ₹4.28 Cr | 1.84% |
| Net Receivables / (Payables) | Cash | ₹4.01 Cr | 1.73% |
| Torrent Pharmaceuticals Ltd | Equity | ₹3.52 Cr | 1.52% |
| Ami Organics Ltd | Equity | ₹3.21 Cr | 1.38% |
| Global Health Ltd | Equity | ₹3.14 Cr | 1.35% |
| Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹3.06 Cr | 1.32% |
| Rainbow Childrens Medicare Ltd | Equity | ₹3.06 Cr | 1.32% |
| 91 DTB 03012025 | Bond - Gov't/Treasury | ₹2.97 Cr | 1.28% |
| Jupiter Life Line Hospitals Ltd | Equity | ₹2.93 Cr | 1.27% |
| Supriya Lifescience Ltd | Equity | ₹2.89 Cr | 1.25% |
| Shaily Engineering Plastics Ltd | Equity | ₹2.45 Cr | 1.06% |
| Thyrocare Technologies Ltd | Equity | ₹2.43 Cr | 1.05% |
| Gufic Biosciences Ltd | Equity | ₹2.35 Cr | 1.01% |
| PB Fintech Ltd | Equity | ₹2.31 Cr | 1.00% |
| Alkem Laboratories Ltd | Equity | ₹2.27 Cr | 0.98% |
| Shilpa Medicare Ltd | Equity | ₹2.19 Cr | 0.94% |
| Eris Lifesciences Ltd Registered Shs | Equity | ₹2.17 Cr | 0.94% |
| RPG Life Sciences Ltd | Equity | ₹2.13 Cr | 0.92% |
| AstraZeneca Pharma India Ltd | Equity | ₹2.11 Cr | 0.91% |
| HealthCare Global Enterprises Ltd | Equity | ₹2.08 Cr | 0.90% |
| Kovai Medical Center & Hospital Ltd | Equity | ₹2.04 Cr | 0.88% |
| 91 DTB 21112024 | Bond - Gov't/Treasury | ₹1.99 Cr | 0.86% |
| Blue Jet Healthcare Ltd | Equity | ₹1.85 Cr | 0.80% |
| Alembic Pharmaceuticals Ltd | Equity | ₹1.85 Cr | 0.80% |
| Laurus Labs Ltd | Equity | ₹1.83 Cr | 0.79% |
| 182 DTB 12122024 | Bond - Gov't/Treasury | ₹1.69 Cr | 0.73% |
| Jubilant Pharmova Ltd | Equity | ₹1.38 Cr | 0.60% |
| Suven Pharmaceuticals Ltd | Equity | ₹1.13 Cr | 0.49% |
| Gland Pharma Ltd | Equity | ₹0.84 Cr | 0.36% |
| 191 DTB 12/12/2024 | Bond - Gov't/Treasury | ₹0.6 Cr | 0.26% |
| 364 DTB 12122024 | Bond - Gov't/Treasury | ₹0.4 Cr | 0.17% |
| 182 DTB 05122024 | Bond - Gov't/Treasury | ₹0.3 Cr | 0.13% |
| 364 DTB 09012025 | Bond - Gov't/Treasury | ₹0.1 Cr | 0.04% |
Allocation By Market Cap (Equity)
Large Cap Stocks
27.07%
Mid Cap Stocks
24.55%
Small Cap Stocks
31.53%
Allocation By Credit Quality (Debt)
AAA
Other Allocation
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹184.92 Cr | 79.71% |
| Basic Materials | ₹5.67 Cr | 2.44% |
| Financial Services | ₹2.31 Cr | 1.00% |
Risk & Performance Ratios
Standard Deviation
This fund
--
Cat. avg.
15.67%
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
0.91
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.69
Higher the better
Fund Managers
Piyush Baranwal
Since February 2024
Ramesh Mantri
Since February 2024
DP
Dheeresh Pathak
Since February 2024
NS
Naitik Shah
Since April 2024
Additional Scheme Detailsas of 31st October 2024
ISIN INF03VN01886 | Expense Ratio 0.68% | Exit Load 1.00% | Fund Size ₹232 Cr | Age 9 months | Lumpsum Minimum ₹500 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
Investment Objective
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Tax Treatment
Capital Gains Taxation:
Dividend Taxation:
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Similar Sector - Healthcare Funds
| Fund name | Expense Ratio | Exit Load | Fund size | 1Y  |
|---|---|---|---|---|
| Motilal Oswal S&P BSE Healthcare ETF Very High Risk | 0.2% | - | ₹28.64 Cr | 43.0% |
| Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Very High Risk | 0.9% | 1.0% | ₹881.52 Cr | 37.2% |
| Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth Very High Risk | 2.3% | 1.0% | ₹881.52 Cr | 35.4% |
| Aditya Birla Sun Life Nifty Healthcare ETF Very High Risk | 0.2% | - | ₹40.84 Cr | 37.9% |
| ITI Pharma and Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹208.21 Cr | 45.8% |
| ITI Pharma and Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹208.21 Cr | 43.1% |
| Mirae Asset Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹2770.21 Cr | 38.2% |
| Mirae Asset Healthcare Fund Regular Growth Very High Risk | 1.9% | 1.0% | ₹2770.21 Cr | 36.2% |
| Nippon India Nifty Pharma ETF Very High Risk | 0.2% | - | ₹852.28 Cr | 36.6% |
| Axis NIFTY Healthcare ETF Very High Risk | 0.3% | - | ₹19.81 Cr | 37.0% |
Risk Level
Your principal amount will be at Very High Risk
Unlock Expert Insights!
Related Articles
Still got questions?
We're here to help.
What is the current NAV of WhiteOak Capital Pharma and Healthcare Fund Direct Growth?
The NAV of WhiteOak Capital Pharma and Healthcare Fund Direct Growth, as of 21-Nov-2024, is ₹12.97.
What is the portfolio composition of WhiteOak Capital Pharma and Healthcare Fund Direct Growth?
The fund's allocation of assets is distributed as 85.20% in equities, 0.00% in bonds, and 14.80% in cash and cash equivalents.
Who manages the WhiteOak Capital Pharma and Healthcare Fund Direct Growth?
The fund managers responsible for WhiteOak Capital Pharma and Healthcare Fund Direct Growth are:-
- Piyush Baranwal
- Ramesh Mantri
- Dheeresh Pathak
- Naitik Shah
Disclaimer: Mutual Fund investments are subject to market risks, read all scheme-related documents carefully. The NAVs of the schemes may go up or down depending upon the factors and forces affecting the securities market including the fluctuations in the interest rates. The past performance of the mutual funds is not necessarily indicative of the future performance of the schemes. Investors are requested to review the prospectus carefully and obtain expert professional advice with regard to specific legal, tax and financial implications of the investment/participation in the scheme.
Trending Mutual Funds Searches
Popular Equity Funds
Popular Debt Funds
©2021-2024 Dezerv. All Rights Reserved
Dezerv Investments Private Limited is a Portfolio Manager with SEBI Registration no. INP000007377, a member of BSE with SEBI Stock Broker Registration no. INZ000303136, and an Investment Manager to Category - I AIF-VCF-Angel Fund with SEBI Registration no. IN/AIF1/22-23/1066.
Mutual Fund distribution services are offered through Dezerv Distribution Services Pvt Limited, a wholly owned subsidiary with AMFI Registration No.: ARN -248439. **Mutual fund investments are subject to market risks, read all scheme related documents carefully.** Terms and conditions of the website are applicable. Privacy policy of the website is applicable.
Dezerv Investments Private Limited is a Portfolio Manager with SEBI Registration no. INP000007377, a member of BSE with SEBI Stock Broker Registration no. INZ000303136, and an Investment Manager to Category - I AIF-VCF-Angel Fund with SEBI Registration no. IN/AIF1/22-23/1066.
Mutual Fund distribution services are offered through Dezerv Distribution Services Pvt Limited, a wholly owned subsidiary with AMFI Registration No.: ARN -248439. **Mutual fund investments are subject to market risks, read all scheme related documents carefully.** Terms and conditions of the website are applicable. Privacy policy of the website is applicable.